Literature DB >> 19717455

Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature.

Knut Tore Lappegård1, Dorte Christiansen, Anne Pharo, Ebbe Billmann Thorgersen, Bernt Christian Hellerud, Julie Lindstad, Erik Waage Nielsen, Grethe Bergseth, Dag Fadnes, Tore G Abrahamsen, E Arne Høiby, Lone Schejbel, Peter Garred, John D Lambris, Morten Harboe, Tom Eirik Mollnes.   

Abstract

Complement component C5 is crucial for experimental animal inflammatory tissue damage; however, its involvement in human inflammation is incompletely understood. The responses to gram-negative bacteria were here studied taking advantage of human genetic complement-deficiencies--nature's own knockouts--including a previously undescribed C5 defect. Such deficiencies provide a unique tool for investigating the biological role of proteins. The experimental conditions allowed cross-talk between the different inflammatory pathways using a whole blood model based on the anticoagulant lepirudin, which does not interfere with the complement system. Expression of tissue factor, cell adhesion molecules, and oxidative burst depended highly on C5, mediated through the activation product C5a, whereas granulocyte enzyme release relied mainly on C3 and was C5a-independent. Release of cytokines and chemokines was mediated to varying degrees by complement and CD14; for example, interleukin (IL)-1beta and IL-8 were more dependent on complement than IFN-gamma and IL-6, which were highly dependent on CD14. IL-1 receptor antagonist (IL-1ra) and IFN-gamma inducible protein 10 (IP-10) were fully dependent on CD14 and inversely regulated by complement, that is, complement deficiency and complement inhibition enhanced their release. Granulocyte responses were mainly complement-dependent, whereas monocyte responses were more dependent on CD14. Notably, all responses were abolished by combined neutralization of complement and CD14. The present study provides important insight into the comprehensive role of complement in human inflammatory responses to gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19717455      PMCID: PMC2732707          DOI: 10.1073/pnas.0903613106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 2.  The tissue factor pathway in disseminated intravascular coagulation.

Authors:  B Østerud; E Bjørklid
Journal:  Semin Thromb Hemost       Date:  2001-12       Impact factor: 4.180

3.  C5 complement deficiency in a Spanish family. Molecular characterization of the double mutation responsible for the defect.

Authors:  Eva Delgado-Cerviño; Gumersindo Fontán; Margarita López-Trascasa
Journal:  Mol Immunol       Date:  2005-01       Impact factor: 4.407

4.  Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients with systemic inflammatory response syndrome.

Authors:  Peter Garred; Jens J Strøm; Lars Quist; Ellen Taaning; Hans O Madsen
Journal:  J Infect Dis       Date:  2003-10-15       Impact factor: 5.226

5.  Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation.

Authors:  Tom Eirik Mollnes; Ole-Lars Brekke; Michael Fung; Hilde Fure; Dorte Christiansen; Grethe Bergseth; Vibeke Videm; Knut Tore Lappegård; Jörg Köhl; John D Lambris
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 6.  The balance between IL-1 and IL-1Ra in disease.

Authors:  William P Arend
Journal:  Cytokine Growth Factor Rev       Date:  2002 Aug-Oct       Impact factor: 7.638

Review 7.  The role of mannose-binding lectin in health and disease.

Authors:  M W Turner
Journal:  Mol Immunol       Date:  2003-11       Impact factor: 4.407

8.  Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.

Authors:  Knut Tore Lappegård; Michael Fung; Grethe Bergseth; Johan Riesenfeld; John D Lambris; Vibeke Videm; Tom Eirik Mollnes
Journal:  Ann Thorac Surg       Date:  2004-03       Impact factor: 4.330

Review 9.  Complement in human diseases: Lessons from complement deficiencies.

Authors:  Marina Botto; Michael Kirschfink; Paolo Macor; Matthew C Pickering; Reinhard Würzner; Francesco Tedesco
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 10.  The dark side of C5a in sepsis.

Authors:  Peter A Ward
Journal:  Nat Rev Immunol       Date:  2004-02       Impact factor: 53.106

View more
  46 in total

Review 1.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

2.  The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load.

Authors:  Kjetil H Egge; Andreas Barratt-Due; Stig Nymo; Julie K Lindstad; Anne Pharo; Corinna Lau; Terje Espevik; Ebbe B Thorgersen; Tom E Mollnes
Journal:  Clin Exp Immunol       Date:  2015-07-19       Impact factor: 4.330

Review 3.  Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host.

Authors:  Jennifer L Krauss; Jan Potempa; John D Lambris; George Hajishengallis
Journal:  Periodontol 2000       Date:  2010-02       Impact factor: 7.589

4.  Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis.

Authors:  Harald F Langer; Kyoung-Jin Chung; Valeria V Orlova; Eun Young Choi; Sunil Kaul; Michael J Kruhlak; Markella Alatsatianos; Robert A DeAngelis; Paul A Roche; Paola Magotti; Xuri Li; Matina Economopoulou; Stavros Rafail; John D Lambris; Triantafyllos Chavakis
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

5.  Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis.

Authors:  Ravi Shankar Keshari; Robert Silasi; Narcis Ioan Popescu; Maulin Mukeshchandra Patel; Hala Chaaban; Cristina Lupu; K Mark Coggeshall; Tom Eirik Mollnes; Steven J DeMarco; Florea Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

6.  Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.

Authors:  Eivind O Samstad; Nathalie Niyonzima; Stig Nymo; Marie H Aune; Liv Ryan; Siril S Bakke; Knut T Lappegård; Ole-Lars Brekke; John D Lambris; Jan K Damås; Eicke Latz; Tom E Mollnes; Terje Espevik
Journal:  J Immunol       Date:  2014-02-19       Impact factor: 5.422

7.  Functional analysis of Ficolin-3 mediated complement activation.

Authors:  Estrid Hein; Christian Honoré; Mikkel-Ole Skjoedt; Lea Munthe-Fog; Tina Hummelshøj; Peter Garred
Journal:  PLoS One       Date:  2010-11-10       Impact factor: 3.240

8.  Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies.

Authors:  Bernt Christian Hellerud; Audun Aase; Tove Karin Herstad; Lisbeth Meyer Naess; Lisa Høyem Kristiansen; Anne-Marie Siebke Trøseid; Morten Harboe; Knut Tore Lappegård; Petter Brandtzaeg; E Arne Høiby; Tom Eirik Mollnes
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

9.  Systemic CD14 inhibition attenuates organ inflammation in porcine Escherichia coli sepsis.

Authors:  Ebbe Billmann Thorgersen; Søren Erik Pischke; Andreas Barratt-Due; Hilde Fure; Julie Katrine Lindstad; Anne Pharo; Bernt Christian Hellerud; Tom Eirik Mollnes
Journal:  Infect Immun       Date:  2013-06-17       Impact factor: 3.441

10.  C1-inhibitor efficiently inhibits Escherichia coli-induced tissue factor mRNA up-regulation, monocyte tissue factor expression and coagulation activation in human whole blood.

Authors:  A Landsem; E W Nielsen; H Fure; D Christiansen; J K Ludviksen; J D Lambris; B Østerud; T E Mollnes; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.